{"id":"https://openalex.org/W2589082299","doi":"https://doi.org/10.1016/j.taap.2017.02.010","title":"Prediction of thyroid C-cell carcinogenicity after chronic administration of GLP1-R agonists in rodents","display_name":"Prediction of thyroid C-cell carcinogenicity after chronic administration of GLP1-R agonists in rodents","alternate_titles":[],"publication_year":2017,"publication_date":"2017-02-16","ids":{"openalex":"https://openalex.org/W2589082299","doi":"https://doi.org/10.1016/j.taap.2017.02.010","mag":"2589082299","pmid":"https://pubmed.ncbi.nlm.nih.gov/28213092"},"language":"en","primary_location":{"id":"doi:10.1016/j.taap.2017.02.010","doi":"https://doi.org/10.1016/j.taap.2017.02.010","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.taap.2017.02.010","pdf_url":null,"source":{"id":"https://openalex.org/S42307217","display_name":"Toxicology and Applied Pharmacology","issn_l":"0041-008X","issn":["0041-008X","1096-0333"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Toxicology and Applied Pharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2589082299"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Willem van den Brink","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I121797337","display_name":"Leiden University","ror":"https://ror.org/027bh9e22","country_code":"NL","type":"education","lineage":["https://openalex.org/I121797337"]},{"id":"https://openalex.org/I4210150351","display_name":"Medicines Evaluation Board","ror":"https://ror.org/05mv4rb84","country_code":"NL","type":"education","lineage":["https://openalex.org/I4210150351"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Willem van den Brink","raw_affiliation_strings":["Systems Pharmacology, Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands; Medicines Evaluation Board, Utrecht, The Netherlands","Medicines Evaluation Board, Utrecht, The Netherlands","Systems Pharmacology, Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Systems Pharmacology, Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands; Medicines Evaluation Board, Utrecht, The Netherlands","institution_ids":["https://openalex.org/I121797337","https://openalex.org/I4210150351"]},{"raw_affiliation_string":"Medicines Evaluation Board, Utrecht, The Netherlands","institution_ids":["https://openalex.org/I4210150351"]},{"raw_affiliation_string":"Systems Pharmacology, Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands","institution_ids":["https://openalex.org/I121797337"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055533333","display_name":"Annette Emerenciana","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I121797337","display_name":"Leiden University","ror":"https://ror.org/027bh9e22","country_code":"NL","type":"education","lineage":["https://openalex.org/I121797337"]},{"id":"https://openalex.org/I4210150351","display_name":"Medicines Evaluation Board","ror":"https://ror.org/05mv4rb84","country_code":"NL","type":"education","lineage":["https://openalex.org/I4210150351"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Annette Emerenciana","raw_affiliation_strings":["Systems Pharmacology, Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands; Medicines Evaluation Board, Utrecht, The Netherlands","Medicines Evaluation Board, Utrecht, The Netherlands","Systems Pharmacology, Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Systems Pharmacology, Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands; Medicines Evaluation Board, Utrecht, The Netherlands","institution_ids":["https://openalex.org/I121797337","https://openalex.org/I4210150351"]},{"raw_affiliation_string":"Medicines Evaluation Board, Utrecht, The Netherlands","institution_ids":["https://openalex.org/I4210150351"]},{"raw_affiliation_string":"Systems Pharmacology, Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands","institution_ids":["https://openalex.org/I121797337"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Francesco Bellanti","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I121797337","display_name":"Leiden University","ror":"https://ror.org/027bh9e22","country_code":"NL","type":"education","lineage":["https://openalex.org/I121797337"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Francesco Bellanti","raw_affiliation_strings":["Systems Pharmacology, Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Systems Pharmacology, Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands","institution_ids":["https://openalex.org/I121797337"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081960928","display_name":"Oscar E. Della Pasqua","orcid":"https://orcid.org/0000-0002-6211-1430","observed_orcids":["https://orcid.org/0000-0002-6211-1430"]},"institutions":[{"id":"https://openalex.org/I121797337","display_name":"Leiden University","ror":"https://ror.org/027bh9e22","country_code":"NL","type":"education","lineage":["https://openalex.org/I121797337"]},{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB","NL"],"is_corresponding":false,"raw_author_name":"Oscar Della Pasqua","raw_affiliation_strings":["Systems Pharmacology, Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands; Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline, Stockley Park, Uxbridge, United Kingdom; Clinical Pharmacology & Therapeutics, UCL, School of Life and Medical Sciences, London, United Kingdom","Clinical Pharmacology & Therapeutics, UCL, School of Life and Medical Sciences, London, United Kingdom","Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline, Stockley Park, Uxbridge, United Kingdom","Systems Pharmacology, Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Systems Pharmacology, Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands; Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline, Stockley Park, Uxbridge, United Kingdom; Clinical Pharmacology & Therapeutics, UCL, School of Life and Medical Sciences, London, United Kingdom","institution_ids":["https://openalex.org/I121797337","https://openalex.org/I188950975","https://openalex.org/I45129253"]},{"raw_affiliation_string":"Clinical Pharmacology & Therapeutics, UCL, School of Life and Medical Sciences, London, United Kingdom","institution_ids":["https://openalex.org/I45129253"]},{"raw_affiliation_string":"Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline, Stockley Park, Uxbridge, United Kingdom","institution_ids":["https://openalex.org/I188950975"]},{"raw_affiliation_string":"Systems Pharmacology, Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands","institution_ids":["https://openalex.org/I121797337"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5090019138","display_name":"Jan Willem van der Laan","orcid":"https://orcid.org/0000-0003-2963-6136","observed_orcids":["https://orcid.org/0000-0003-2963-6136"]},"institutions":[{"id":"https://openalex.org/I121797337","display_name":"Leiden University","ror":"https://ror.org/027bh9e22","country_code":"NL","type":"education","lineage":["https://openalex.org/I121797337"]},{"id":"https://openalex.org/I4210150351","display_name":"Medicines Evaluation Board","ror":"https://ror.org/05mv4rb84","country_code":"NL","type":"education","lineage":["https://openalex.org/I4210150351"]}],"countries":["NL"],"is_corresponding":true,"raw_author_name":"Jan Willem van der Laan","raw_affiliation_strings":["Division of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands; Medicines Evaluation Board, Utrecht, The Netherlands. Electronic address: jw.vd.laan@cbg-meb.nl","Division of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands","Medicines Evaluation Board, Utrecht, The Netherlands"],"raw_orcid":"https://orcid.org/0000-0003-2963-6136","affiliations":[{"raw_affiliation_string":"Division of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands; Medicines Evaluation Board, Utrecht, The Netherlands. Electronic address: jw.vd.laan@cbg-meb.nl","institution_ids":["https://openalex.org/I121797337","https://openalex.org/I4210150351"]},{"raw_affiliation_string":"Division of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands","institution_ids":["https://openalex.org/I121797337"]},{"raw_affiliation_string":"Medicines Evaluation Board, Utrecht, The Netherlands","institution_ids":["https://openalex.org/I4210150351"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5090019138"],"corresponding_institution_ids":["https://openalex.org/I121797337","https://openalex.org/I4210150351"],"apc_list":{"value":4200,"currency":"USD","value_usd":4200},"apc_paid":null,"fwci":0.8743,"has_fulltext":false,"cited_by_count":16,"citation_normalized_percentile":{"value":0.71963534,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":97},"biblio":{"volume":"320","issue":null,"first_page":"51","last_page":"59"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.1770000010728836,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.1770000010728836,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.08389999717473984,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10433","display_name":"Carcinogens and Genotoxicity Assessment","score":0.0714000016450882,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9729999899864197},{"id":"https://openalex.org/keywords/c-cell-hyperplasia","display_name":"C-cell hyperplasia","score":0.8489999771118164},{"id":"https://openalex.org/keywords/exenatide","display_name":"exenatide","score":0.9129999876022339},{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":0.9950000047683716},{"id":"https://openalex.org/keywords/lixisenatide","display_name":"lixisenatide","score":1.0},{"id":"https://openalex.org/keywords/pharmacokinetic-pharmacodynamic-modeling","display_name":"pharmacokinetic-pharmacodynamic modeling","score":0.8880000114440918},{"id":"https://openalex.org/keywords/pre-neoplastic-lesions","display_name":"pre-neoplastic lesions","score":0.640999972820282},{"id":"https://openalex.org/keywords/drug-safety-prediction","display_name":"drug safety prediction","score":0.37400001287460327}],"concepts":[{"id":"https://openalex.org/C114246631","wikidata":"https://www.wikidata.org/wiki/Q187661","display_name":"Carcinogen","level":2,"score":0.6860946416854858},{"id":"https://openalex.org/C526584372","wikidata":"https://www.wikidata.org/wiki/Q16399","display_name":"Thyroid","level":2,"score":0.5768215656280518},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4462316930294037},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4292324185371399},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.39595526456832886},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3699341416358948},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3145325183868408},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.13064080476760864}],"mesh":[{"descriptor_ui":"D000067757","descriptor_name":"Glucagon-Like Peptide-1 Receptor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000067758","descriptor_name":"Glucagon-Like Peptide-2 Receptor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069450","descriptor_name":"Liraglutide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000069450","descriptor_name":"Liraglutide","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":true},{"descriptor_ui":"D000077270","descriptor_name":"Exenatide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000097789","descriptor_name":"Glucagon-Like Peptide-1 Receptor Agonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":true},{"descriptor_ui":"D011237","descriptor_name":"Predictive Value of Tests","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012377","descriptor_name":"Rodentia","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013964","descriptor_name":"Thyroid Neoplasms","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D013964","descriptor_name":"Thyroid Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D014688","descriptor_name":"Venoms","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014688","descriptor_name":"Venoms","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":true},{"descriptor_ui":"D016208","descriptor_name":"Databases, Factual","qualifier_ui":"Q000639","qualifier_name":"trends","is_major_topic":false},{"descriptor_ui":"D017711","descriptor_name":"Nonlinear Dynamics","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1016/j.taap.2017.02.010","doi":"https://doi.org/10.1016/j.taap.2017.02.010","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.taap.2017.02.010","pdf_url":null,"source":{"id":"https://openalex.org/S42307217","display_name":"Toxicology and Applied Pharmacology","issn_l":"0041-008X","issn":["0041-008X","1096-0333"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Toxicology and Applied Pharmacology","raw_type":"journal-article"},{"id":"pmid:28213092","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28213092","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Toxicology and applied pharmacology","raw_type":"Journal Article"},{"id":"pmh:oai:eprints.ucl.ac.uk.OAI2:1542459","doi":null,"is_oa":false,"landing_page_url":"https://discovery.ucl.ac.uk/id/eprint/1542459/","pdf_url":null,"source":{"id":"https://openalex.org/S4306400024","display_name":"UCL Discovery (University College London)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I45129253","host_organization_name":"University College London","host_organization_lineage":["https://openalex.org/I45129253"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Toxicology and Applied Pharmacology , 320 pp. 51-69. (2017)","raw_type":"Article"},{"id":"mag:2740803628","doi":null,"is_oa":false,"landing_page_url":"http://discovery.ucl.ac.uk/1542459/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320321644","display_name":"College ter Beoordeling van Geneesmiddelen","ror":"https://ror.org/041evnj42"},{"id":"https://openalex.org/F4320332163","display_name":"U.S. Food and Drug Administration","ror":"https://ror.org/034xvzb47"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":23,"referenced_works":["https://openalex.org/W1988311543","https://openalex.org/W1990804906","https://openalex.org/W2004409542","https://openalex.org/W2023220695","https://openalex.org/W2033954313","https://openalex.org/W2038245016","https://openalex.org/W2054837530","https://openalex.org/W2076472674","https://openalex.org/W2081655349","https://openalex.org/W2119433310","https://openalex.org/W2127063807","https://openalex.org/W2140004965","https://openalex.org/W2147684061","https://openalex.org/W2151567146","https://openalex.org/W2154180317","https://openalex.org/W2158351892","https://openalex.org/W2166969890","https://openalex.org/W2295455801","https://openalex.org/W2344371104","https://openalex.org/W2464012090","https://openalex.org/W2504539829","https://openalex.org/W2531087303","https://openalex.org/W6658905472"],"related_works":["https://openalex.org/W2020816546","https://openalex.org/W2158351892","https://openalex.org/W2158762809","https://openalex.org/W7214492207","https://openalex.org/W2166969890","https://openalex.org/W7223465595","https://openalex.org/W2589617314","https://openalex.org/W4410208160"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2589082299","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2022,"cited_by_count":4},{"year":2020,"cited_by_count":3},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2017-02-24T00:00:00"}
